Search results | antibiotics


Antibiotics Partnering Terms and Agreements

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in antibiotics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Antibiotics partnering contract documents Top antibiotics deals by value   The Antibiotics Partnering Terms and more »


Antibiotics partnering analysis in biopharma industry

The  last two years alone has seen $1.9 billion spent on antibiotics partnering by the biopharma industry.


The term antibiotics was first used in 1942 by Selman Waksman and his collaborator

Cubist Pharmaceuticals – Shaping developments in antibiotics

Cubist Pharmaceuticals is a biopharmaceutical company developing and commercializing medications for acute care in hospitals and surgical environments.

Pharma and biotech clinical stage partnering – recent trends 2009 to 2014

Partnering trends for the top pharma and biotech companies reviewed with over 2,000 deals analyzed – including summary biopharma deal financials

Cubist Pharma, the next acquisition target for big pharmaceuticals

The timing may be right for a takeover of Cubist Pharmaceuticals.

Current Agreements Deal Analysis Update : June 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in May 2014.

Cubist: M&A activity 2009-2014

Cubist has acquired a few companies in the last five years with its biggest purchase of $800 million of Optimer Pharmaceuticals.      

Cubist: Partnering activity 2009-2014

Cubist, a leading biopharmaceutical company focusses in the discovery, development and commercialization of novel acute care therapies.

Current Agreements Deal Analysis Update : March 2014

This month we provide you with an overview of deal analysis life science deal making activity, covering partnering, M&A and financing in February 2014

Hospira: King of the injectables

Chicago based Hospira is a specialist provider of generic injectables and infusion technologies in the healthcare industry.


Sorry, your search returned no results.


AstraZeneca to spin out antibiotics business

AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company

Collaboration agreement for developing gram-negative antibiotics

Euprotec has entered into an alliance with Cantab Anti-infectives as they seek to develop improved antibiotics to treat multidrug resistant Gram negative bacterial infections.

Asset purchase agreement for topical antibiotics and pain products

Actavis has entered into agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration.

Pfizer big pharma deals Sequella for TB antibiotics

Sequella has entered pharma deals with Pfizer, a big pharma company, for the licensing rights to Sutezolid, a tuberculosis antibiotic.

GlaxoSmithKline big pharma deals with DKSH for antibiotics

Big pharma company, GlaxoSmithKline, has signed a pharma deals agreement with DKSH for them to provide contract sales services in both private clinics and trade channel for the big pharma company’s antibiotic product line. 

Rib-X Pharmaceuticals and Sanofi sign research collaboration agreement on novel classes of antibiotics

Rib-X Pharmaceuticals has announced the signature of an exclusive worldwide research collaboration agreement and option for license with Sanofi for novel classes of antibiotics resulting from Rib-X’s RX-04 program for the treatment of resistant Gram-positive and resistant Gram-negative pathogens. 

Roche licenses OP0595 from Meiji and Fedora

Roche, Meiji Seika Pharma and Fedora have entered into a license agreement for the development and commercialization of OP0595

Big pharma, Merck Serono joins hand with Lupin to expand its product portfolio

Big pharma, Merck Serono announced the establishment of a long-term strategic partnership with Lupin Limited.

Cepheid signs pharma deal with 3 big pharmas

Cepheid announced a new pharma deal with AstraZeneca, Cubist Pharmaceuticals, and GSK intended to promote transformational change in infectious disease therapy.

C3 Jian raises $60 million in Series D financing

C3 Jian, Inc., a private company focused on developing proprietary drugs with an initial focus on improving oral healthcare, announced today the close of its Series D financing raising total proceeds of $60.5 million.